8-K: Calidi Biotherapeutics Secures $1.2M in Direct Offering

Calidi Biotherapeutics announced a $1.2 million registered direct offering of common stock at $1.17 per share to fund working capital and general corporate purposes.

Summary

• Calidi Biotherapeutics, Inc. (CLDI) has entered into a stock purchase agreement for a registered direct offering.
• The company will issue and sell 1,025,640 shares of its common stock at a purchase price of $1.17 per share.
• The offering is expected to generate gross proceeds of approximately $1.2 million before expenses.
• The net proceeds are intended for working capital and general corporate purposes.
• The offering closed on September 21, 2026, and was made under an effective shelf registration statement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating the company is securing necessary funds for operations but at a price that reflects current market conditions.

Positives

• Secured $1.2 million in gross proceeds to support operations.
• The offering was conducted efficiently without the need for underwriters or placement agents.
• The company has a clear use of proceeds for working capital and general corporate purposes.
• The offering was made under an existing effective shelf registration statement, streamlining the process.

Negatives

• The offering price of $1.17 per share may indicate a depressed valuation or a need for immediate capital.
• The company is issuing new shares, which could lead to dilution for existing shareholders.

Risks

• The company may not be able to raise sufficient capital to support its current and anticipated clinical trials.
• Early clinical trial results may not predict final outcomes.
• There is a risk that the company may not receive FDA approval for its therapeutic candidates.
• Risks related to changes in applicable laws or regulations.
• Manufacturing and supply chain matters could pose challenges.
• The availability of capital and other resources is a concern.
• Changes in business, market, economic, or competitive conditions could adversely affect the company.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. The filing also references ongoing IND-enabling studies for its lead candidate CLD-401 and advancement of its pipeline utilizing the RedTail platform.

Management Comments

• Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (Calidi or the Company), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company's common stock, in a registered direct offering, at a per share purchase price of $1.17.
• The gross proceeds to Calidi from the registered direct offering, before deducting offering expenses payable by the Company, are expected to be approximately $1.2 million.
• Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.

Industry Context

StockSavvy.ai notes that capital raises are common for early-stage biotechnology companies like Calidi Biotherapeutics, especially when advancing drug candidates through clinical trials. The registered direct offering structure suggests a need for speed and efficiency in securing funds, often utilized when a company believes its stock is undervalued or when market conditions are volatile.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The capital raised is intended to support the company's operations and development, potentially benefiting long-term shareholder value.
• Creditors and suppliers will likely see continued operational support, reducing immediate concerns about payment.

Next Steps

• Utilize net proceeds for working capital and general corporate purposes.
• Continue IND-enabling studies for CLD-401.
• Advance pipeline utilizing the RedTail platform.
• Continue to incorporate in situ T-cell engagers in solid tumors.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' as the capital raise provides necessary operational runway but the offering price suggests potential valuation concerns and dilution. Further progress in clinical trials and regulatory approvals will be key catalysts.

Keywords

biotechnology, genetic medicines, registered direct offering, common stock, working capital, corporate purposes, shelf registration statement, clinical trials